Yonhap news on December 3rd, Lee Sang-yu, head of the flow analysis of the Central Epidemic Prevention Countermeasures Headquarters of South Korea, said at a regular press conference on the 3rd that the side effect exemption requirements of overseas pharmaceutical companies on the coronavirus vaccine are not aimed at South Korea, but to the world. In response, the Korean Disease Control Agency and the Food and Drug Safety Department said that they would negotiate to ensure the safety and effectiveness of the vaccine and eliminate related concerns.
Li Xiangyu said that it usually takes at least 10 years to complete a vaccine, which is much more time-consuming to verify than research and development. Now this time has shrunk to one year, so people naturally have more concerns about the safety and efficacy of vaccines than long-term proven vaccines. The Office of Disease Control will cooperate with the Food and Drug Service to develop a thorough and efficient vaccine approval process.
Gao eirong, spokesman of the Department of Disease Control, said recently that the government is negotiating with many coronavirus vaccine manufacturers in many countries, and the specific progress, contract terms and procurement volume should not be made public.
At present, the priority of vaccination against the novel coronavirus in South Korea has not been announced, but it is expected that front-line medical staff and vulnerable people will be the priority targets for vaccination. The government has allocated 44 million doses of COVID-19 vaccine in the budget this year and next year, which can be used by 85% of the people. However, details such as signing the contract, the signing time and the purchase quantity have not been announced.